Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
JD Health International (6618 HK)
Watchlist
355
Analysis
Consumer Staples
•
China
JD Health International Inc. operates drug stores. The Company retails Chinese and Western medicines, nutrition products, health care products, and other products. JD Health International markets its products throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
JD Health International
•
22 Nov 2023 08:55
JD Health (6618.HK) 23Q3 - Performance Decline Is Inevitable, but There Is Upside Room for Valuation
JD Health's 23H2 results won't be satisfactory, dragging down full year growth, which may not recover until 24H2. But stock price has priced in...
Xinyao (Criss) Wang
Follow
332 Views
Share
bullish
•
JD Health International
•
18 Nov 2023 19:02
[JD Health (6618 HK, BUY, TP HK$52) TP Change]: A COVID Hiccup but Environment Is Turning Positive
JDH reported lower-than-expected Q3 results, leading to reductions in profit estimates and target price, but we maintain a buy rating due to...
Blue Lotus Research Institute
Follow
356 Views
Share
bearish
•
JD Health International
•
21 Aug 2023 08:55
JD Health (6618.HK) 23H1 - The Beautiful Story Is Over; It's Time to Face Reality
We had anticipated JD Health's declining growth in previous insights, but 23Q2 performance was indeed ugly. JD Health's facing dilemmas in policies...
Xinyao (Criss) Wang
Follow
250 Views
Share
bullish
•
JD Health International
•
18 Aug 2023 08:33
[JD Health (6618 HK, BUY, TP HK$65) TP Change]: Benefit of Alternative Channel Starts to Show
With years of tightening NDRL and the recent hardline anti-corruption campaign, more pharmaceuticals and patients are looking for alternative...
Blue Lotus Research Institute
Follow
458 Views
Share
bearish
•
JD Health International
•
17 Aug 2023 12:52
JD Health 1H2023: Reports Operating Profits; Margin Upside Is Very Limited
Though JD Health made an OPM of 5.7% in 1Q2023, 1H2023 OPM was 3.5% in line with our analysis that OPM in excess of 2-3% may not be possible in the...
Shifara Samsudeen, ACMA, CGMA
Follow
370 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.30.3
x